{
    "clinical_study": {
        "@rank": "3083", 
        "arm_group": {
            "arm_group_label": "Target subject population 1500", 
            "description": "Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-centre, cross-sectional study planned to be conducted in China. The study\n      aims to observe about 1500 asthma patients who have already received budesonide/formoterol\n      combination treatment by physicians' determination and whose medications are aligned with\n      the package insert of budesonide/formoterol approved in China."
        }, 
        "brief_title": "The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "The asthma control rate achieved by budesonide/formoterol in clinical practice in China"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Clinical diagnosis of asthma at least 6 months;\n\n          2. Prescribed with budesonide/formoterol treatment at least 3 months before enrolled;\n\n          3. Has used the same maintenance dose of budesonide/formoterol for at least 4 weeks\n             before enrolled.\n\n        Exclusion Criteria:\n\n          1. Participation in any clinical study within 3 months;\n\n          2. Have COPD history/suspicious COPD;\n\n          3. \u2265 10 pack years of smoking history\n\n          4. Used any other asthma maintenance medication accompanied with budesonide/formoterol\n             within 3 months before enrolled\n\n          5. With asthma exacerbation (defined as asthma symptom deterioration resulting\n             oral/rectal/parenteral GCS medication or emergency room treatment or hospitalisation)\n             within 4 weeks before enrolled"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Asthma patients from clinic"
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785901", 
            "org_study_id": "NIS-RCN-SYM-2012/1"
        }, 
        "intervention": {
            "arm_group_label": "Target subject population 1500", 
            "description": "without interventions", 
            "intervention_name": "without interventions", 
            "intervention_type": "Other", 
            "other_name": "without interventions"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Formoterol", 
                "Symbicort"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "asthma", 
            "control rate", 
            "budesonide/formoterol", 
            "Non-Interventional study"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baotou", 
                        "country": "China", 
                        "state": "Inner Mongolia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China", 
                        "state": "Shandong"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China", 
        "overall_contact": {
            "email": "jingjing.jiang@astrazeneca.com", 
            "last_name": "AstraZeneca Clinical Study Information", 
            "phone": "86-21-60301308"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: China Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The rate of controlled and partly controlled asthma according to the definition of Global Initiative for Asthma", 
            "safety_issue": "No", 
            "time_frame": "one day"
        }, 
        "reference": {
            "citation": "Makar AB, McMartin KE, Palese M, Tephly TR. Formate assay in body fluids: application in methanol poisoning. Biochem Med. 1975 Jun;13(2):117-26."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785901"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The rate of completely controlled and well controlled asthma according to Asthma Control Test's score", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "The average frequency of reliever use in previous week", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}